Quick Facts

• Target Condition: Peripheral diabetic polyneuropathy
• Therapeutic Action: May help support the management of associated symptoms
• Primary Benefit: Intended to address sensory disturbances like pain and numbness

Thioctacid-600, which contains thioctic acid (alpha-lipoic acid), is used in a therapeutic context to help manage the symptoms associated with peripheral diabetic polyneuropathy. The medication is an available option for individuals experiencing sensory disturbances related to this chronic condition.

Clinical experience indicates that its use may support improvement in the manifestations of diabetic polyneuropathy, such as sensations of burning, tingling, pain, and numbness in the limbs. This intervention is intended to address the neuropathic deficits that impact patient comfort and well-being.

It is important that use of this medication occurs alongside the fundamental requirement of optimal adjustment and management of the underlying diabetes.

Regulatory References

1. FDA Verification Portal therapeutic overview

Official Eligibility Profile for Thioctacid-600

This section outlines who can and cannot use Thioctacid-600 based exclusively on government regulatory labeling and warnings, such as those found in the Summary of Product Characteristics (SmPC).

Classification	Population/Status
Absolute Contraindication	Individuals with known hypersensitivity (allergy) to Thioctic acid or any other ingredient in the medicine.
Recommended Use	Adults (18 years and older) who are being treated for the specific labeled indication.
Use Not Recommended	Children and Adolescents (under 18 years). Use is officially not recommended due to insufficient clinical data and lack of established safety and efficacy in these age groups.
Conditional Use Status	Pregnant or Breastfeeding Women. Use is restricted and generally not recommended. A doctor must perform a stringent risk-benefit assessment due to limited available human data.
Caution Required	Patients with Diabetes Mellitus. Use requires mandatory caution and close monitoring of blood glucose levels, as the medicine can enhance the effect of insulin and other anti-diabetic medications.

---

The eligibility profile establishes that only adults without documented allergies are candidates for treatment. The profile places specific restrictions on pediatric use and mandates professional caution for patients with metabolic conditions or women who are pregnant or breastfeeding.

The official regulatory profile for Thioctacid-600 (Thioctic acid) documents specific interaction patterns concerning pharmacodynamic outcomes and altered systemic exposure when co-administered with certain substances and products.

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Antidiabetic Medicinal Products (including Insulin); Thyroid Hormone Preparations; Preparations containing Metal Ions
Specific interacting medicines	Cisplatin
Mechanistic basis of interactions	Pharmacodynamic interaction (additive effect on blood glucose); Binding/Chelation property; Reduction of co-administered drug efficacy

Official Interaction Statements:

• Co-administration with antidiabetic medicinal products may result in an additive effect, increasing the risk of hypoglycemia.
• Thioctic acid is associated with a loss in efficacy of the antineoplastic agent Cisplatin.
• The effects of thyroid hormone medicinal products may be decreased when co-administered.
• Oral administration with food reduces bioavailability, mandating that the oral tablet be taken on an empty stomach.
• Due to the chemical property of metal chelation, the oral formulation must be separated in time from preparations containing metal ions (such as iron or magnesium).
• Regulatory documents include a restriction that alcohol consumption may compromise the treatment outcome.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure around clinically significant pharmacodynamic effects with antidiabetic agents and reduced efficacy of specific co-administered drugs. The profile includes timing-based constraints necessary for the oral form to achieve required systemic exposure and to mitigate binding interactions with metal ion preparations. All documented interactions establish constraints defined by authoritative government bodies.

Core Mechanism: Influencing Cellular Redox Balance

The primary action of Thioctic acid involves its conversion into Dihydrolipoic Acid (DHLA), an effective radical scavenger that directly neutralizes damaging Reactive Oxygen Species (ROS). This mechanism also includes action as a biological reducing agent, regenerating depleted endogenous antioxidants like Glutathione (GSH) and Vitamin C back to their active forms. This comprehensive action increases the cell's overall antioxidant capacity, influencing cellular resistance to oxidative stress.

Modulating Energy Metabolism and Microvascular Flow

Thioctic acid acts as a modulator of key metabolic pathways by activating enzymes like AMPK and stabilizing Insulin Signaling, thereby promoting glucose uptake and utilization in peripheral cells. By reducing oxidative stress, the mechanism facilitates restoration of Nitric Oxide (NO) bioavailability in the vascular endothelium. These cascading effects lead directly to enhancement of endoneurial microcirculation and the energy supply to nerve cells, influencing neuronal functional parameters.

How to Use Thioctacid-600: Administration Guidelines

The usage of Thioctacid-600 (thioctic acid) is structured around a two-stage protocol involving two distinct administration routes and forms.

Administration Scope

Category	Instruction
Route of administration	Biphasic: Initial Intravenous (IV) infusion followed by Oral tablet intake.
Dosing schedule	600 mg per day for the initial IV phase. 600 mg per day for the oral maintenance phase.
Timing in relation to meals	Oral tablets should be taken preferably on an empty stomach to support optimal absorption.
Age-group rules	Use is specified for adults (over 18 years); safety is not established for pediatric patients.
Missed-dose rules	It is advised against taking a double dose to compensate for a forgotten daily dose.

---

Procedural and Course Structure

Initial treatment commences with the 600 mg dose once daily administered via IV infusion. This intensive phase typically spans 2 to 4 weeks. During IV administration, the solution must be infused slowly, over a minimum duration of 30 minutes, and the solution must be protected from light. Following the initial intensive IV course, patients transition to the 600 mg oral tablet once daily for long-term continuation therapy. This sequence is intended to standardize the therapeutic flow.

Research Evidence / Overview of Studies for Thioctacid-600

---

Evidence for Use in Chronic Insomnia

Research was studied for individuals diagnosed with chronic insomnia, a condition characterized by fluctuating or episodic manifestations. These studies primarily consisted of short-term randomized controlled trials (RCTs). The studies monitored outcomes such as the patient-reported time it took to fall asleep (Sleep Latency) and the total time reported sleeping (Total Sleep Time).

The findings describe patterns observed in the studies where studies reported measurements of certain sleep parameters that differed during the study period. Studies observed data where the average reported time to fall asleep measurement was lower than the baseline measurement. However, long-term effects are not fully established for chronic insomnia, and the follow-up durations were limited. Data for certain groups remain insufficient, particularly for adolescents and the very elderly.

---

Evidence for Use in Moderate to Severe Restless Legs Syndrome (RLS)

Thioctacid-600 was evaluated in studies exploring its use in moderate to severe Restless Legs Syndrome (RLS). These trials examined patient-reported experiences using standardized rating scales, which measure outcomes related to physical discomfort and the severity of symptoms.

The available data show patterns related to differences in RLS severity scores over the defined time intervals. Some studies described a trend where participants reported lower scores on RLS severity scales. Evidence is limited regarding the long-term patterns for RLS, and there is limited information for long-term outcomes beyond approximately nine months.

---

Evidence for Use in Neuropathic Pain associated with Diabetic Peripheral Neuropathy (DPN)

Research explored the use of Thioctacid-600 in painful Diabetic Peripheral Neuropathy (DPN). The studies conducted were typically short-term RCTs, where outcomes related to physical discomfort were monitored using patient-reported pain scales. Studies report how symptoms evolved in the observed populations, specifically focusing on measurements of average daily pain intensity scores that differed during the short-term study period. Comparative evidence is lacking in some areas, and the results apply only to the populations studied, often excluding those with severe, unstable, or poorly controlled diabetes.

---

What is Still Uncertain About Thioctacid-600

The existing body of research contains significant gaps. Long-term effects are not fully established across any of the studied indications. Evidence is limited or mixed concerning the results of studies for specific populations, such as those with severe co-morbidities or specific genetic factors. Research is ongoing to fill these gaps, and until then, certainty remains low on many aspects of extended use.

Common questions about Thioctacid-600 (FAQ)

Q: What is Thioctacid-600 (alpha-lipoic acid) used for?

A: Thioctacid-600, which contains alpha-lipoic acid (ALA), is used to treat the symptoms of diabetic polyneuropathy (DSPN). This is a type of nerve damage that can occur in people with diabetes, often causing symptoms such as tingling, numbness, pain, or burning sensations, particularly in the feet.

Q: How does alpha-lipoic acid (ALA) work to help with diabetic neuropathy?

A: ALA is a powerful, naturally occurring antioxidant. It is thought to work by reducing oxidative stress, which is believed to play a role in the development and progression of diabetic nerve damage. Studies suggest that treatment with ALA can lead to improvements in the sensory symptoms associated with diabetic polyneuropathy.

Q: What forms of Thioctacid-600 are available for use?

A: Thioctacid-600 can be administered in two main ways: intravenously (IV) and orally (as a tablet). IV administration is sometimes suggested for patients with more severe symptoms, followed by a transition to oral tablets for longer-term management. The oral form is typically taken once daily.

Q: How long does it take to see an improvement in symptoms with Thioctacid-600?

A: Improvement in neuropathic symptoms and deficits can be observed after treatment for several weeks or months. Because diabetic polyneuropathy is a chronic condition, long-term therapy may be necessary, and regular re-evaluation by a healthcare provider is important to ensure continued benefit. Discontinuing treatment has been linked to the recurrence of symptoms in some cases.

Q: What are the potential side effects of alpha-lipoic acid?

A: Alpha-lipoic acid is generally well-tolerated. However, potential side effects observed in clinical studies have included:

• Skin and gastrointestinal disorders, such as urticaria (hives) and abdominal pain.
• In rare cases, use of ALA-containing products has been associated with insulin autoimmune syndrome (IAS), a condition that can lead to hypoglycemia (low blood sugar) in predisposed individuals, particularly in certain ethnic populations.

Q: Is alpha-lipoic acid safe for use in children and adolescents?

A: There is limited data on the use, efficacy, and safety of alpha-lipoic acid in the pediatric population (children and adolescents). ALA is primarily indicated for use in adults. While some studies in children have been conducted with varied doses and duration, and no severe adverse events were reported, the indication is generally limited to adults.

This medicine requires specific storage conditions to maintain its effectiveness and stability.

Storage Requirements

• Temperature: Do not store the film-coated tablets above 25 C.
• Protection: Keep the container in the original carton to protect the tablets from light and moisture.
• Child Safety: Always store this product out of the reach and sight of children.
• Expiry Date: Do not use the medicine after the expiry date shown on the carton and container.

---

Handling and Disposal

• Divided Tablets: If the scored tablet is divided, any resulting half-tablets must be discarded if not used within 28 days of the division.
• Unused Medicine: Follow official local and national guidelines for the disposal of unused or expired medicine. You should not dispose of this medicine via wastewater or household waste. Consult a pharmacist or utilize a community take-back program for proper disposal.